These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 19049345)

  • 21. Phosphodiesterase 2A as a therapeutic target to restore cardiac neurotransmission during sympathetic hyperactivity.
    Liu K; Li D; Hao G; McCaffary D; Neely O; Woodward L; Ioannides D; Lu CJ; Brescia M; Zaccolo M; Tandri H; Ajijola OA; Ardell JL; Shivkumar K; Paterson DJ
    JCI Insight; 2018 May; 3(9):. PubMed ID: 29720569
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Natriuretic peptides block synaptic transmission by activating phosphodiesterase 2A and reducing presynaptic PKA activity.
    Hu F; Ren J; Zhang JE; Zhong W; Luo M
    Proc Natl Acad Sci U S A; 2012 Oct; 109(43):17681-6. PubMed ID: 23045693
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Novel Inhibition Modality for Phosphodiesterase 2A.
    Nakashima K; Matsui H
    SLAS Discov; 2020 Jun; 25(5):498-505. PubMed ID: 32343157
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Target Engagement of a Phosphodiesterase 2A Inhibitor Affecting Long-Term Memory in the Rat.
    Gu G; Scott T; Yan Y; Warren N; Zhang A; Tabatabaei A; Xu H; Aertgeerts K; Gomez L; Morse A; Li YW; Breitenbucher JG; Massari E; Vivian J; Danks A
    J Pharmacol Exp Ther; 2019 Sep; 370(3):399-407. PubMed ID: 31253692
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Application of Structure-Based Design and Parallel Chemistry to Identify a Potent, Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor.
    Helal CJ; Arnold EP; Boyden TL; Chang C; Chappie TA; Fennell KF; Forman MD; Hajos M; Harms JF; Hoffman WE; Humphrey JM; Kang Z; Kleiman RJ; Kormos BL; Lee CW; Lu J; Maklad N; McDowell L; Mente S; O'Connor RE; Pandit J; Piotrowski M; Schmidt AW; Schmidt CJ; Ueno H; Verhoest PR; Yang EX
    J Med Chem; 2017 Jul; 60(13):5673-5698. PubMed ID: 28574706
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis, 18F-Radiolabelling and Biological Characterization of Novel Fluoroalkylated Triazine Derivatives for in Vivo Imaging of Phosphodiesterase 2A in Brain via Positron Emission Tomography.
    Schröder S; Wenzel B; Deuther-Conrad W; Teodoro R; Egerland U; Kranz M; Scheunemann M; Höfgen N; Steinbach J; Brust P
    Molecules; 2015 May; 20(6):9591-615. PubMed ID: 26016549
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of an Orally Bioavailable, Brain-Penetrating, in Vivo Active Phosphodiesterase 2A Inhibitor Lead Series for the Treatment of Cognitive Disorders.
    Mikami S; Sasaki S; Asano Y; Ujikawa O; Fukumoto S; Nakashima K; Oki H; Kamiguchi N; Imada H; Iwashita H; Taniguchi T
    J Med Chem; 2017 Sep; 60(18):7658-7676. PubMed ID: 28759228
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of selective inhibition of cyclic GMP hydrolyzing phosphodiesterases 2 and 5 on learning and memory processes and nitric oxide synthase activity in brain during aging.
    Domek-Łopacińska K; Strosznajder JB
    Brain Res; 2008 Jun; 1216():68-77. PubMed ID: 18499090
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro and in vivo characterisation of Lu AF64280, a novel, brain penetrant phosphodiesterase (PDE) 2A inhibitor: potential relevance to cognitive deficits in schizophrenia.
    Redrobe JP; Jørgensen M; Christoffersen CT; Montezinho LP; Bastlund JF; Carnerup M; Bundgaard C; Lerdrup L; Plath N
    Psychopharmacology (Berl); 2014 Aug; 231(16):3151-67. PubMed ID: 24577516
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phosphodiesterase inhibition by naloxone augments the inotropic actions of beta-adrenergic stimulation.
    Park WK; Chang CH; Chae JE; Kim MH; Cho YL; Ahn DS
    Acta Anaesthesiol Scand; 2009 Sep; 53(8):1043-51. PubMed ID: 19572940
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacological characterization of a novel potent, selective, and orally active phosphodiesterase 2A inhibitor, PDM-631.
    Maehara S; Arakawa K; Hoshida K; Nagasue H; Chida N; Nakao K; Furusako S
    Eur J Pharmacol; 2017 Sep; 811():110-116. PubMed ID: 28587776
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vivo effects of phosphodiesterase inhibition on basal cyclic guanosine monophosphate levels in the prefrontal cortex, hippocampus and cerebellum of freely moving rats.
    Marte A; Pepicelli O; Cavallero A; Raiteri M; Fedele E
    J Neurosci Res; 2008 Nov; 86(15):3338-47. PubMed ID: 18655195
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TAK-915, a phosphodiesterase 2A inhibitor, ameliorates the cognitive impairment associated with aging in rodent models.
    Nakashima M; Suzuki N; Shiraishi E; Iwashita H
    Behav Brain Res; 2019 Dec; 376():112192. PubMed ID: 31521738
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The phosphodiesterase 2A controls lymphatic junctional maturation via cGMP-dependent notch signaling.
    Carlantoni C; Liekfeld LMH; Hemkemeyer SA; Schreier D; Saygi C; Kurelic R; Cardarelli S; Kalucka J; Schulte C; Beerens M; Mailer RK; Schäffer TE; Naro F; Pellegrini M; Nikolaev VO; Renné T; Frye M
    Dev Cell; 2024 Feb; 59(3):308-325.e11. PubMed ID: 38159569
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The inhibitory profile of Ibudilast against the human phosphodiesterase enzyme family.
    Gibson LC; Hastings SF; McPhee I; Clayton RA; Darroch CE; Mackenzie A; Mackenzie FL; Nagasawa M; Stevens PA; Mackenzie SJ
    Eur J Pharmacol; 2006 May; 538(1-3):39-42. PubMed ID: 16674936
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Binding of cyclic nucleotides to phosphodiesterase 10A and 11A GAF domains does not stimulate catalytic activity.
    Matthiesen K; Nielsen J
    Biochem J; 2009 Oct; 423(3):401-9. PubMed ID: 19689430
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Natriuretic peptide receptor-A is functionally expressed on bullfrog retinal Müller cells.
    Cao LH; Yang XL
    Brain Res Bull; 2007 Jan; 71(4):410-5. PubMed ID: 17208659
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of a Novel Series of Pyrazolo[1,5-a]pyrimidine-Based Phosphodiesterase 2A Inhibitors Structurally Different from N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915), for the Treatment of Cognitive Disorders.
    Mikami S; Kawasaki M; Ikeda S; Negoro N; Nakamura S; Nomura I; Ashizawa T; Kokubo H; Hoffman ID; Zou H; Oki H; Uchiyama N; Hiura Y; Miyamoto M; Itou Y; Nakashima M; Iwashita H; Taniguchi T
    Chem Pharm Bull (Tokyo); 2017; 65(11):1058-1077. PubMed ID: 29093293
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PDE2A Inhibition Enhances Axonal Sprouting, Functional Connectivity, and Recovery after Stroke.
    Bechay KR; Abduljawad N; Latifi S; Suzuki K; Iwashita H; Carmichael ST
    J Neurosci; 2022 Nov; 42(44):8225-8236. PubMed ID: 36163142
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modulation of cAMP/cGMP signaling as prevention of congenital heart defects in Pde2A deficient embryos: a matter of oxidative stress.
    Cardarelli S; Biglietto M; Orsini T; Fustaino V; Monaco L; de Oliveira do Rêgo AG; Liccardo F; Masciarelli S; Fazi F; Naro F; De Angelis L; Pellegrini M
    Cell Death Dis; 2024 Feb; 15(2):169. PubMed ID: 38395995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.